Cancer Vaccine ImMucin Shows Promising Results After Clinical Trial

medical-daily-vaxil-article

Researchers in Israel have taken a truly innovative approach toward treating cancer in their attempt to harness the body’s own immune system to fight off the disease. Based on clinical trials for a cancer vaccine, called ImMucin, results look promising. According to Vaxil BioTherapeurtics, ImMucin’s makers, in Nes Ziona, Israel, the cancer vaccine triggers an immune response in about 90 percent of all types of cancer.

Full article available at the Medical Daily: http://www.medicaldaily.com/cancer-vaccine-immucin-shows-promising-results-after-clinical-trial-may-work-90-all-316342

Leave a Reply

Your email address will not be published. Required fields are marked *